Myomodulation begins with chemistry — but its clinical expression is mechanical.
Myomodulation introduces a distinctive approach to aesthetic medicine based on molecular precision. Its injectable preparation is built around a stereochemically defined chiral acid combined with a refined lipid carrier designed to support controlled interaction within the biological environment.
Rather than acting through muscular paralysis or by depositing persistent volumizing material, Myomodulation is conceived as a system in which chemical input signals interact with muscular and surrounding viscoelastic tissues.
The muscle can therefore be modeled as a biological transfer system in which chemical input is translated into a mechanical response. This response is clinically expressed through myoplasty, myopexy and myotension — changes in muscular shape, position and tension contributing to controlled three-dimensional tissue redistribution.
Navigate through the molecular, biological and biomechanical foundations of Myomodulation.
Myomodulation uses an injectable preparation designed around a stereochemically defined aromatic acid associated with a refined lipid carrier system. Its function is not to create implanted volume, but to initiate controlled chemical interactions capable of being translated into a mechanical tissue response.
The principal active molecular component is a defined stereochemical form of an aromatic acid with an acid–base behavior characterized by a pKa of approximately 6.6.
Its stereochemical configuration is relevant because three-dimensional molecular geometry can influence how a molecule interacts with biological structures.
The refined lipid phase acts as a carrier and dispersion medium. Following subcutaneous placement, it supports progressive interaction between the preparation and the underlying muscular environment.
The intended mechanism is therefore distinct from direct intramuscular bolus placement and from the deposition of a volumizing implant.
The lipid fraction contains esterified fatty-acid structures that contribute to the physicochemical behavior, stability and tissue distribution of the preparation.
The preparation is not designed to produce contour change by leaving persistent bulk within the tissues.
Myomodulation is conceptually distinct from techniques based on pharmacologic interruption of neuromuscular transmission.
It contains no cross-linked gel or particulate implant intended to remain as a permanent structural volume.
Molecular configuration is treated as a functional parameter rather than simply a chemical identity.
The clinical effect does not depend on the injected material remaining permanently within the treated tissues.
The treatment concept is based on controlled tissue interaction rather than intentional tissue destruction, denervation or volumetric implantation.
At the core of the Myomodulation preparation is a stereochemically defined chiral aromatic acid. Its three-dimensional molecular configuration, acid–base behavior and interaction with the lipid carrier contribute to the physicochemical profile of the preparation.
Chirality means that two molecules may share the same atomic composition while differing in their three-dimensional spatial configuration. In biological systems, this distinction can be important because molecular recognition is inherently three-dimensional.
The aromatic acid used in the Myomodulation preparation is therefore considered not simply by its chemical formula, but by its specific stereochemical configuration.
Defined stereochemical configuration rather than a nonspecific racemic representation.
Weak-acid behavior characterized by a pKa of approximately 6.6, which influences the relative proportions of ionized and non-ionized molecular species in a biological environment.
The molecular behavior of the aromatic acid must be interpreted together with the refined lipid carrier, which influences dispersion and tissue availability.
Biological interaction depends on molecular geometry, local concentration, protonation state and the physicochemical environment surrounding the molecule.
Biological macromolecules are themselves three-dimensional and often chiral. A molecule's spatial configuration can therefore influence its interaction with proteins, lipid structures and other molecular environments.
The enantiopure configuration promotes stereoselective, non-necrotic interactions with tissue proteins, supporting functional tissue remodeling while preserving tissue viability.
Improved selectivity through three-dimensional molecular recognition.
Predictable local kinetics within the intended tissue environment.
No coagulative necrosis pathway under the defined clinical conditions of use.
The aromatic acid used in the Myomodulation preparation is characterized by a defined stereochemical configuration. Chirality matters because biological structures are themselves three-dimensional: two molecules with the same atomic composition can behave differently when their spatial configurations are mirror images.
A chiral molecule cannot be perfectly superimposed on its mirror image. The two mirror-image forms are called enantiomers.
Although enantiomers share the same molecular formula and many bulk physicochemical properties, they may interact differently with chiral biological macromolecules such as proteins, enzymes, receptors and membrane-associated structures.
Stereochemistry therefore adds a critical dimension to molecular identity: biological activity depends not only on what atoms are present, but also on how those atoms are arranged in three-dimensional space.
Molecules with the same molecular formula and connectivity but a different three-dimensional arrangement of their atoms.
A pair of stereoisomers that are non-superimposable mirror images of one another.
The enantiomer exhibiting the greater desired biological or pharmacological activity for a particular molecular system.
The corresponding enantiomer showing lower desired activity or a different biological profile.
A 1:1 mixture of two enantiomers, containing equal proportions of both mirror-image configurations.
Development of a defined single-enantiomer form from a previously racemic compound when stereochemical separation provides a meaningful pharmacological advantage.
Change in configuration at one stereogenic center, producing a different stereoisomer rather than a simple mirror-image inversion.
Processes capable of converting one stereochemical form into another, depending on molecular structure and biological environment.
Describes clockwise or counter-clockwise rotation of plane-polarized light. Optical rotation does not define the absolute R/S configuration.
Absolute stereochemical configuration assigned according to the Cahn–Ingold–Prelog priority rules.
These descriptors are not interchangeable: an R enantiomer is not necessarily dextrorotatory (+), and an S enantiomer is not necessarily levorotatory (−).
The aromatic acid used in the Myomodulation preparation should therefore not be regarded simply as a generic aromatic compound. Its defined stereochemical configuration is part of its molecular identity.
A defined enantiomeric form provides a more controlled molecular starting condition than an unspecified stereochemical mixture and supports the concept of stereoselective interaction within the tissue environment.
In the Myomodulation model, this controlled molecular interaction contributes to the chemical input signal that is subsequently translated by the muscular and viscoelastic tissue system into a mechanical response.
The aromatic acid is not delivered as an isolated molecule. It is incorporated within a refined lipid phase that contributes to formulation stability, dispersion and controlled interaction with the subcutaneous and underlying muscular environment.
The lipid phase should not be viewed simply as an inert vehicle. It contributes to the physicochemical environment in which the active aromatic acid is transported and presented to the tissues.
Following subcutaneous placement, the carrier supports progressive distribution of the preparation toward the underlying muscular structures without requiring direct intramuscular bolus injection.
The refined lipid environment contributes to preservation of the physicochemical characteristics of the preparation during storage, handling and administration.
After subcutaneous placement, the lipid phase influences how the active molecular component partitions and distributes within the local tissue environment.
Carrier composition influences molecular availability over time and therefore contributes to the temporal profile of local chemical interaction.
The carrier forms part of the interface between the injected preparation and the surrounding adipose, connective and muscular tissue compartments.
Molecular behavior cannot be interpreted independently of the vehicle in which the molecule is delivered. The refined lipid phase influences partitioning, dispersion and local availability of the stereochemically defined aromatic acid.
The Myomodulation model therefore distinguishes the anatomical injection plane from the biological environment in which the response is expressed.
The biological behavior of the Myomodulation preparation depends not only on the active aromatic acid, but also on the local physicochemical environment created by its carrier system. At tissue interfaces, molecular geometry, ionization, lipid partitioning and protein surface chemistry collectively determine how the chemical signal is expressed.
The refined carrier creates a local environment in which the stereochemically defined aromatic acid can interact with biological macromolecular surfaces.
These interactions may involve a combination of hydrophobic forces, ionic interactions, hydrogen bonding and stereochemical recognition, depending on local molecular conditions.
The intended Myomodulation mechanism is fundamentally different from a destructive chemical reaction based on irreversible protein coagulation. The objective is a functional molecular response while preserving viable tissue architecture.
Aromatic and lipid-compatible molecular regions can interact with hydrophobic domains at biological interfaces.
The degree of ionization of the aromatic acid changes according to local pH relative to its pKa, influencing molecular behavior and distribution.
Three-dimensional molecular configuration can influence how a chiral molecule approaches and interacts with biological macromolecular surfaces.
The lipid phase modifies local partitioning and molecular availability, contributing to the kinetics of tissue exposure.
Protein surfaces contain regions with different charge, polarity, hydrophobicity and three-dimensional geometry. A chiral weak aromatic acid presented within a lipid environment can therefore encounter a complex set of molecular interfaces.
Within the Myomodulation model, these interactions are interpreted as transient physicochemical events capable of initiating a biological signal without requiring the permanent destruction of the macromolecular structure.
Myomodulation is conceived as a sequence in which controlled solvent–carrier–protein interactions initiate a biological signal that can be translated into an immediate mechanical response, while the clinical effect does not require intentional coagulative tissue necrosis.
The acid dissociation constant, pKa, describes the equilibrium between the protonated and deprotonated forms of a weak acid. Together with the local pH, it determines the fraction of molecules present in ionized and non-ionized forms.
For a weak acid: HA represents the protonated, electrically neutral form, while A− represents the deprotonated, negatively charged form.
When pH > pKa, the deprotonated form progressively predominates.
Ionization changes several physicochemical properties of a molecule, including its electrical charge, aqueous solubility, lipid partitioning and interaction with biological interfaces.
The pKa therefore does not act as an isolated “safety parameter.” Instead, it helps predict how a weak acid exists chemically within a given pH environment.
In tissue, this equilibrium contributes to the molecular conditions under which diffusion, membrane partitioning and protein-interface interactions occur.
At physiological pH, the deprotonated charged form is predominant.
At physiological pH, phenol remains overwhelmingly in its protonated, non-ionized form.
At pH 7.4, an aromatic acid with a pKa near 6.6 exists predominantly in its charged, ionized form. This generally favors interaction with aqueous environments and reduces unrestricted partitioning of the entire molecular population into hydrophobic phases.
By contrast, phenol at the same pH remains predominantly non-ionized, which is consistent with a substantially different physicochemical partitioning profile.
These differences help explain why two aromatic compounds should not be assumed to behave similarly merely because both contain an aromatic ring.
The combination of a defined aromatic acid pKa, stereochemical identity and refined lipid carrier establishes a specific acid–base and partitioning environment. At physiological pH, the predominance of the ionized molecular form contributes to a controlled physicochemical context for local molecular interaction.
This provides a mechanistic distinction from highly lipophilic, predominantly non-ionized compounds whose tissue behavior can involve substantially different membrane and protein interactions.
Biological interactions are three-dimensional. A chiral molecule may therefore interact differently with a biological interface depending on its spatial configuration and on the geometry, polarity and chemical environment of the interaction site.
Proteins and other biological macromolecules possess complex three-dimensional surfaces containing hydrophobic, ionic, polar and hydrogen-bonding environments. Molecular interaction therefore depends on more than chemical composition alone.
Two enantiomeric forms can contain the same atoms and functional groups while presenting those groups differently in space. Their interactions with a chiral biological environment may consequently differ.
This is the fundamental rationale for considering stereochemical identity as a functional parameter in the chemistry of Myomodulation.
Spatial orientation determines how molecular functional groups are presented to a biological interface.
Protonation state changes molecular charge and contributes to aqueous, lipid and protein-interface behavior.
Lipid distribution, concentration, exposure time and tissue architecture influence local molecular availability.
The Myomodulation model combines a stereochemically defined molecular signal, its acid–base behavior and its lipid environment. Together, these parameters determine the physicochemical conditions under which local tissue interaction occurs.
The objective is not indiscriminate protein coagulation or chemical destruction, but a controlled molecular interaction capable of initiating a functional biological response while preserving tissue architecture.
Myomodulation can be represented as a functional system in which a controlled chemical input interacts with muscular and surrounding viscoelastic tissues and is translated into a mechanical output.
This is a conceptual biomechanical model: the muscle is not literally an electronic transfer function, but it can be modeled as a biological system whose response depends on the nature, intensity, distribution and timing of the chemical input.
The muscular system receives the local chemical signal within a complex biological environment composed of muscle fibers, fascia, connective tissue, adipose tissue, extracellular matrix and vascular interfaces.
Its mechanical response depends on the existing architecture, tension, orientation and viscoelastic properties of these structures.
In simplified systems language: Y(t) = Hmuscle[X(t)]. The equation is a conceptual representation of biological transformation, not a claim that muscular behavior follows a fixed linear mathematical law.
Fiber orientation, thickness, insertion geometry and existing muscular contour influence the direction in which a mechanical response is expressed.
Fascia and connective-tissue planes constrain and redistribute forces, influencing translation of muscular deformation into visible contour change.
A thicker subcutaneous fat layer can reduce effective diffusion toward the underlying muscular environment and alter the spatial distribution of the chemical input.
Pre-existing muscular tone and tissue tension influence how a local response is transmitted across the surrounding viscoelastic system.
Two anatomical regions exposed to a similar chemical input may not produce an identical visible response because the transfer system itself is different.
Muscle geometry, fiber orientation, fascia, fat thickness and baseline tension modify how the initial chemical signal is translated into shape, position and tension changes.
This is why Myomodulation must be interpreted as a chemistry–anatomy–biomechanics interaction rather than as the action of a molecule in isolation.
The mechanical output is therefore expressed primarily as redistribution of existing tissue geometry, rather than creation of contour through persistent injected volume.
The chemical signal becomes clinically relevant only when it is translated into mechanical change. In the Myomodulation model, this output is expressed through three complementary dimensions: shape, lifting and tension.
Myoplasty describes a change in muscular geometry and visible contour without requiring the creation of new implanted volume.
Myopexy describes the lifting of the treated anatomical structure as a whole, produced by controlled muscular reshaping and mechanical redistribution without the addition of volume.
Myotension describes a change in the mechanical tension state of muscular and surrounding viscoelastic tissues.
The visible result is produced by redistribution of existing tissue geometry. Projection can increase while the global anatomy is lifted, without requiring an increase in total tissue volume.
Vectors describe the direction of mechanical action. They indicate how projection and contour are redistributed within the treated anatomical structure.
Tensors describe the distribution of tension and deformation across multiple spatial directions and determine the final three-dimensional architecture.
The final contour results from the interaction between directional redistribution and distributed tissue tension, producing shape change, lifting and firmness.
These three terms should not be interpreted as three completely independent biological events. A change in shape can modify projection; increased projection can coexist with global lifting; and changes in tissue tension contribute to both contour and firmness.
In gluteal myopexy, the buttock can be lifted as a whole while the point of maximal projection becomes more projected. The point of maximal projection is not required to move superiorly and, with progressive Myomodulation, may move inferiorly while the global lifting effect remains clearly visible.
At the inferior boundary of the buttock, myopexy is expressed by elevation and reshaping of the infragluteal sulcus, contributing directly to the visible lifting of the entire gluteal architecture.
Myoplasty, myopexy and myotension therefore represent three complementary descriptions of the same three-dimensional mechanical response.
Myomodulation evaluates the treated tissue as a coupled biomechanical system rather than as isolated anatomical points.
The visible outcome is a 3D change in contour, projection, lifting and firmness generated by redistribution of the existing muscular–viscoelastic system, without creating new volume.
The clinical effect of Myomodulation does not depend on the permanent presence of injected material. The molecular components undergo progressive biological clearance, while the mechanically remodeled tissue can continue to express the resulting three-dimensional change.
Myomodulation should not be interpreted according to the logic of a persistent filler or implanted volumizer. The injected preparation acts as a temporary chemical input to a living muscular–viscoelastic system.
The aromatic acid component is cleared on a short biological time scale, approximately within 24 hours.
The refined arachidonic-acid lipid carrier remains longer within the biological environment and is progressively cleared over approximately three weeks.
The visible contour depends on the continued physical presence of implanted or injected bulk.
The injected preparation provides a temporary chemical signal, while the visible outcome derives from mechanical reorganization of existing tissue.
Molecular elimination and clinical duration represent two different biological time scales. The injected preparation does not need to remain permanently inside the tissue for the resulting biomechanical change to remain clinically visible.
The chemical input initiates a tissue response. Once the muscular–viscoelastic architecture has been mechanically reorganized, the visible result is no longer explained by the presence of retained material.
Molecular components interact transiently with the target biological system.
INPUTThe molecular components are progressively eliminated according to their individual kinetic profiles.
ELIMINATIONShape, lifting, projection and tissue tension can remain altered after material clearance.
CLINICAL EXPRESSIONMyomodulation can be understood as a continuous sequence in which molecular chemistry is converted into biological interaction, muscular processing and three-dimensional mechanical expression. The final clinical result is therefore not an isolated chemical event, but the output of a coupled biomechanical system.
The injectable preparation provides a controlled molecular input defined by its composition, stereochemical organization, solvent environment and lipid carrier.
Muscle acts as a biological transfer function, converting the transient chemical input into a mechanically expressed change in tissue geometry and tension.
The observable output is expressed through myoplasty, myopexy and myotension, producing three-dimensional redistribution of the existing muscular–viscoelastic architecture.
Existing muscular geometry is reorganized, modifying visible convexities, concavities and projection.
GEOMETRIC REMODELINGThe treated anatomical structure is lifted globally. In gluteal remodeling, projection may increase while the buttock and infragluteal sulcus are visibly elevated.
GLOBAL LIFTINGMechanical tension is redistributed across muscular, fascial and surrounding viscoelastic structures.
TENSION REDISTRIBUTIONMyomodulation therefore reshapes the visible anatomy through redistribution of existing tissue, rather than through persistent volumetric augmentation.
The injected preparation provides the chemical input, but the final clinical architecture emerges from the response of the muscular–viscoelastic system.
The same principle explains why the clinical effect can continue after molecular clearance: the injected material is not the final structural result. The tissue itself becomes the mechanically remodeled system.
The clinical outcome must therefore be interpreted as a biomechanical transformation generated by biological processing of a transient chemical signal.
Define the direction of intended mechanical redistribution and contribute to the displacement of projection and contour.
Determine how mechanical forces and deformation are distributed through the treated three-dimensional tissue architecture.
Shape, projection, lifting and tension become integrated within a single coordinated biomechanical result.
Selected scientific sources provide broader context for the chemical, biological and biomechanical framework presented on this page. Publications directly related to Myomodulation are available in the dedicated scientific library.
Arachidonic acid and related lipid mediators participate in multiple signaling pathways involved in cellular regulation, inflammatory signaling and tissue homeostasis . This literature provides broader biological context for understanding lipid-mediated interactions within living tissue.
READ THE REFERENCED STUDY →
A Hypothesis of Mechanism of Action and Classification of Peels
Luc Dewandre · Alain Tenenbaum · Desmer Destang
Procedures in Cosmetic Dermatology Series: Chemical Peels
3rd Edition · Elsevier · 2020
ISBN: 978-0-323-65389-3
This chapter examines the chemistry underlying chemical tissue interactions and proposes a mechanistic framework for understanding how the properties of chemical compounds influence their biological effects.
It provides additional scientific context for the concepts of molecular chemistry, stereochemistry and controlled tissue interaction discussed throughout this Myomodulation Chemistry page.
An earlier edition of this chapter was associated with DOI 10.1016/B978-1-4377-1924-6.00001-X . The publisher's DOI link is no longer active, so the current Elsevier book record and ISBN are used here as the primary publication reference.
Independent literature helps explain chemical and biological mechanisms relevant to lipid signaling, molecular interactions, stereochemistry and tissue physiology.
MECHANISTIC CONTEXTPublications directly related to Myomodulation document the technique, tissue observations, clinical concepts and scientific development specific to this field.
DIRECT DOCUMENTATIONAccess the dedicated Myomodulation scientific publications page for publications, books, scientific documentation and further material related to chemistry, tissue interaction, histology, biomechanics and clinical Myomodulation .
VIEW SCIENTIFIC PUBLICATIONSMyomodulation chemistry describes how a transient molecular input can interact with living tissue, be processed by the muscular system and ultimately be expressed as a three-dimensional biomechanical response.
The injected preparation acts as a chemical input. Its role is not to remain as implanted bulk, but to initiate a controlled interaction with tissue.
The muscular and viscoelastic system then acts as a biological transfer function, converting this molecular signal into measurable changes in shape, lifting and tension.
Molecular composition, stereochemistry, solvent behavior and lipid-mediated transport determine how the preparation can interact with biological tissue.
CONTROLLED CHEMICAL SIGNALThe final tissue response is not determined by chemistry alone. Living muscular and viscoelastic structures process the signal and convert it into a biomechanical response.
BIOLOGICAL PROCESSINGThe visible clinical expression is produced through myoplasty, myopexy and myotension, reorganizing existing tissue geometry within an isovolumetric system.
3D MYOMODULATIONThe injected components are progressively cleared from the tissue.
The clinical effect does not require continued retention of the injected material.
Chemistry provides the signal. Biology processes it. Biomechanics determines the visible result.
Myomodulation can be understood through several complementary scientific perspectives. Explore the molecular, biological, biomechanical and clinical dimensions that together define its three-dimensional tissue remodeling model.
Explore formulation, stereochemistry, molecular interactions, lipid-mediated transport, solvent behavior and the chemical principles underlying Myomodulation.
EXPLORE CHEMISTRYExamine how controlled chemical signals interact with living tissue and how muscular and viscoelastic structures participate in the biological response.
EXPLORE TISSUE SCIENCEUnderstand how vectors, tensors, muscular architecture and viscoelastic behavior determine the three-dimensional redistribution of shape, lift and tension.
EXPLORE BIOMECHANICSExplore how molecular and biomechanical processes are expressed clinically through geometric remodeling, global lifting and redistribution of tissue tension.
EXPLORE CLINICAL SCIENCEAccess publications, books and scientific material related to chemistry, tissue interaction, histology, biomechanics and the development of Myomodulation.
VIEW PUBLICATIONSConnect the molecular input, biological transfer function and mechanical output within one coherent three-dimensional and isovolumetric scientific framework.
EXPLORE THE SCIENCEContinue through the Myomodulation scientific resources and explore the mechanisms connecting chemical input, muscular processing and three-dimensional mechanical output.
Key scientific questions concerning the formulation, tissue interaction, clearance and biomechanical expression of Myomodulation.
The injected preparation acts primarily as a chemical input. It initiates a controlled interaction with living tissue rather than functioning as implanted volumetric material.
The muscular and viscoelastic system subsequently processes this molecular signal and contributes to the final biomechanical response.
No. The Myomodulation model is fundamentally isovolumetric.
Existing tissue volume is redistributed through changes in geometry, projection, lifting and tension rather than through the addition of retained injected bulk.
Stereochemistry influences how molecular structures interact with biological targets.
In Myomodulation chemistry, molecular configuration is therefore relevant to understanding the selectivity and predictability of tissue interaction.
The refined lipid carrier participates in the distribution and tissue contact of the molecular preparation.
Its role is part of the controlled chemical delivery system and should not be confused with permanent tissue augmentation.
No. The presence of the injected material and the duration of the biomechanical response are two different phenomena.
The injected components are progressively cleared, while the downstream biomechanical response may outlast their molecular presence.
Muscle functions as a biological transfer system between the molecular input and the mechanical output.
The chemical signal interacts with living tissue, while muscular architecture and viscoelastic behavior contribute to the way the resulting mechanical response is expressed in three dimensions.
These three mechanical expressions describe complementary aspects of three-dimensional Myomodulation rather than separate volumizing effects.
Not necessarily. Myopexy refers to global lifting of the treated anatomical structure.
In gluteal remodeling, the buttock and infragluteal sulcus may be visibly elevated while the point of maximal projection becomes more projected and may progressively move inferiorly.
Myomodulation depends on controlled interaction with the targeted tissue environment.
A thicker subcutaneous fat layer can increase the distance between the injected preparation and the muscular target, thereby influencing diffusion and effective tissue contact.
No. Pharmacokinetic clearance and biomechanical duration are distinct concepts.
Clearance describes the fate of the injected molecular components. The clinical result reflects the tissue response that follows the initial chemical interaction.
No. Chemistry defines and initiates the molecular input, but the final response also depends on biology and biomechanics.
Myomodulation is therefore best understood as an integrated system:
Scientific publications, books and further documentation related to Myomodulation are available in the dedicated Scientific Publications section.
VIEW SCIENTIFIC PUBLICATIONS →Myomodulation chemistry supplies the molecular input; living tissue converts that input into a three-dimensional biomechanical response.
Understanding the science is the first step. Choose how you would like to learn, access or discuss Myomodulation in clinical practice.
Move from scientific understanding to practical application through dedicated Myomodulation training and hands-on workshops.
Access the preparation and related professional resources through the dedicated professional ordering platform.
Discuss a clinical case remotely, including patient selection, anatomical strategy, treatment planning or a specific Myomodulation indication.
Contact us for scientific, professional, educational or business enquiries related to Myomodulation.
SCIENCE → TRAINING → CLINICAL PRACTICE